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SUMMARY. In patients with chronic hepatitis C virus (HCV)
infection, steatosis and fibrosis have been shown to be
inversely associated with total cholesterol (TC) and low-
density lipoprotein cholesterol. Steatosis and fibrosis have
also been found to be associated with triglyceride (TG) levels;
though, the direction of the relationship is inconsistent
across studies. The objective of this study was to assess
whether viral level and histological factors are associated
with the serum lipid profile in a treatment-naı̈ve cohort with
chronic HCV genotype 1 infection. Participants were from
the prospective Study of Viral Resistance to Antiviral Ther-
apy (Virahep-C). Fasting lipid profiles were analysed for 160
African Americans and 170 Caucasian Americans. Linear
regression was used to evaluate associations of each lipid
with viral load and liver disease. TG levels were significantly
and directly associated with HCV levels (P = 0.0034) and
steatosis (P < 0.0001). Other lipid parameters were signifi-
cantly lower in those with fibrosis [HDLc (P = 0.001) and
TC levels (P = 0.004)] than in those without fibrosis. In
patients with HCV genotype 1 infection, more severe liver
disease was associated with lower lipid levels, with the
exception of TG levels that were directly related to steatosis.
The direct relationship between viral load and TG levels is
consistent with proposed the mechanisms of very low den-
sity lipoprotein/HCV particle secretion. In contrast, the direct
relationship between TG level and steatosis is inconsistent
with posited mechanisms of HCV-induced steatosis, a possi-
ble reflection of HCV genotype 1 infection and a metabolic
aetiology of steatosis.
Keywords: cholesterol, fibrosis, hepatitis C, hepatitis C virus,
lipoprotein, steatosis, serum lipids.
In the United States, approximately 3.2 million noninstitu-
tionalized people have chronic hepatitis C virus (HCV)
infection [1,2]. The estimated direct US health care cost of
HCV in 1997, including liver transplantation for which
chronic HCV ranks as the leading indication, was $1.8 bil-
lion [3,4]. These statistics underscore the significant public
health burden of chronic HCV infection.
Recent reports suggest that serum lipids may be rele-
vant to HCV and its life cycle. Compared to people without
HCV infection, people with chronic HCV tend to have
lower total cholesterol (TC), low-density lipoprotein cho-
lesterol (LDLc) and high-density lipoprotein cholesterol
(HDLc) levels [5–8]. Triglycerides (TG) have also been
associated with HCV infection with reports of both lower
[5–8] and higher levels [9], the opposite direction of the
relationships possibly reflecting the impact of different host
factors.
In both noninfected and HCV-infected cohorts, lipids have
been associated with liver disease measures, including stea-
tosis, fibrosis and cirrhosis [10–14]. In a non-HCV exposed
cohort, TG and HDLc were directly and inversely related to
steatosis, respectively, and no significant association was
found with LDLc [11]. Among chronic HCV-infected cohorts,
inverse relationships of TC and LDLc with steatosis and
fibrosis have been reported [12,13]. TGs have also been
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associated with steatosis, although inversely in a study of
genotype 3 infection [13] and directly in another report of
genotype 1 infection [10]. Furthermore, compared to control
patients, liver cirrhosis has been associated with lower LDLc,
HDLc and TC levels, with lower TC levels limited to patients
with chronic active hepatitis [14].
Findings from in vitro work support a mechanism
involving HCV/lipoprotein complexes and LDL receptor or
scavenger receptor-B1 (SR-B1)-meditated HCV entry into
hepatocytes [15–18]. However, the LDL receptor-mediated
mechanism is controversial [19,20]. Entry of free HCV (not
bound with lipoproteins) may also occur through SR-B1 or
CD81 [20–22]. Other work posits a process of HCV viral
particle assembly and secretion related to very low density
lipoprotein (VLDL) metabolic pathways [23–27]. In addition,
the interaction of the HCV core with microsomal TG transfer
protein has been shown to disrupt VLDL secretion resulting
in intrahepatic TG accumulation, a possible mechanism of
HCV-induced steatosis [26].
The relationships among serum lipids, liver disease, and
possible HCV entry, replication and secretion processes are
complex. This study characterizes factors associated with
serum lipids in a treatment-naı̈ve cohort with chronic HCV
genotype 1 infection. This report is relevant to in vitro and
animal model studies that propose potential pathogenic
mechanisms of HCV-induced liver damage, as well as




Participants were drawn from The Study of Viral Resistance
to Antiviral Therapy of Chronic Hepatitis C (Virahep-C)
cohort, which has been previously described [28]. In brief,
the Virahep-C study included 196 African American (AA)
and 205 Caucasian American (CA) treatment-naı̈ve patients
with HCV genotype 1 infection to investigate the clinical,
immunological, virological and host genetic factors that
contribute to the racial disparity in antiviral treatment effi-
cacy. Participants between the ages of 18 and 70 years with
chronic HCV infection were treated with pegylated interferon
alfa-2a and ribavirin combination therapy for up to
48 weeks. Lipid profile analyses were conducted among
participants who consented to participate in host genetic
studies (n = 374) and had available stored fasting serum
samples at baseline (n = 335). Five participants who
reported use of lipid-lowering agents at the screening eval-
uation were excluded from the statistical analysis. The final
sample included in this analysis consisted of 330 partici-
pants (160 AA and 170 CA). This study was approved by
the University of Pittsburghs Institutional Review Board,
and informed consent was received from the human subjects
or their representatives. The study protocol conforms to the
ethical guidelines of the 1975 Declaration of Helsinki as
reflected in a priori approval by the institutions human re-
search committee.
Study measures
Estimates of the lipid fractions, TG, LDLc, HDLc and TC, were
obtained through analysis of stored fasting serum samples at
the Heinz Nutrition Laboratory in the Department of Epide-
miology at the University of Pittsburgh using spectrophoto-
metric methods. If TG levels were <400 mg/dL, the
Friedewald formula was used to calculate LDLc indirectly
(LDLc = TC ) HDLc ) 0.20 · TG) [29]. Samples for which
TG levels were at least 400 mg/dL (n = 3) had LDLc assessed
directly. Dyslipidaemia was defined using the cut-offs from
the National Cholesterol Education Program (NCEP) Adult
Treatment Panel III recommendations as any of the follow-
ing: LDLc ‡ 130 mg/dL, HDLc < 40 mg/dL, TC ‡ 200 mg/
dL or TG ‡ 150 mg/dL [30].
Biopsy-assessed liver disease measures included inflam-
mation, fibrosis score, fat score and iron score. Inflammation
and fibrosis were assessed using the criteria of the histolog-
ical activity index (HAI) (range 0–12 and 0–6, respectively)
by a single hepatopathologist [31,32]. An Ishak fibrosis
score of at least three was classified as severe fibrosis, and
steatosis was defined as a fat score of greater than zero
(range 0–4) representing at least 5% fat involvement of
hepatic tissue. An iron score of 0, 1 or 2 was assigned
according to the amount of iron deposits in hepatic tissue.
Summing non-Ishak fibrosis scores from the HAI, a total HAI
inflammation score was calculated. HAI inflammation scores
between 0–6 were classified as mild, 7–11 as moderate and
12 or greater as severe. Total HAI inflammation, Ishak
fibrosis and fat scores were also analysed. Other nonbiopsy
serological liver disease indicators included alanine and
aspartate aminotransferase (ALT and AST, respectively),
alkaline phosphatase, total bilirubin, the international nor-
malized ratio (INR), white blood cell count (WBC), platelet
count, serum ferritin and the per cent iron saturation [iron/
total iron-binding capacity (TIBC)].
Statistical analysis
Categorical measures were summarized as frequency and per
cent with differences across groups on nominal scales (race,
gender, health insurance status, employment status, smok-
ing status, alcohol consumption of at least two drinks per
week, history of diabetes and hypertension, HCV genotype
and severe fibrosis) assessed using a Pearsons chi-squared
test or the exact equivalent. Differences in categorical mea-
sures across ordered groups (education, HAI scores and iron
scores) were assessed using a Jonckheere–Terpstra test or the
exact equivalent. Continuous measures were summarized as
medians and interquartile ranges with differences in group
distributions assessed using the Wilcoxon rank sum or a
 2010 Blackwell Publishing Ltd
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Table 1 Cohort characteristics
Feature* Overall (n = 330) AA (n = 160) CA (n = 170) P
Demographics
Age (years) 48 (43, 52) 48 (45, 52) 47 (42, 52) 0.07
Male 216 (65.5) 106 (66.3) 110 (64.7) 0.77
Health insurance (m = 6) 0.008
Uninsured 58 (17.9) 21 (13.4) 37 (22.2) 0.04
Public 79 (24.4) 49 (31.2) 30 (18.0) 0.006
Private 187 (57.7) 87 (55.4) 100 (59.9) 0.42
Education (m = 8)§ 0.008
Less than high school 61 (18.9) 36 (23.1) 25 (15.1) 0.07
High school degree 78 (24.2) 41 (26.3) 37 (22.3) 0.16
Some college 105 (32.6) 50 (32.1) 55 (33.1) 0.16
College degree or more 78 (24.2) 29 (18.6) 49 (29.5) –
Employed (m = 4) 204 (62.6) 101 (63.9) 103 (61.3) 0.63
Health risk behaviours
Current smoker (m = 6) 128 (39.5) 65 (41.7) 63 (37.5) 0.44
Consumes ‡2 alcoholic
drinks/week (m = 7)
66 (20.4) 38 (24.2) 28 (16.9) 0.10
General clinical features
BMI (m = 5) 28.4 (25.2, 32.4) 29.3 (26.6, 33.9) 27.4 (24.4, 31.4) <0.001
Waist-to-hip ratio (m = 23) 0.9 (0.9, 1.0) 0.9 (0.8, 1.0) 0.9 (0.8, 1.0) 0.44
Diabetic 31 (9.4) 24 (15.0) 7 (4.1) <0.001
Hypertensive 97 (29.4) 64 (40.0) 33 (19.4) <0.001
Viral characteristics
Log10 HCV level (m = 1) 6.5 (5.6, 6.7) 6.4 (5.6, 6.7) 6.5 (5.6, 6.8) 0.25
HCV genotype– 0.002
1, NOS 25 (7.6) 10 (6.3) 15 (8.8) 0.38
1a 177 (53.6) 79 (49.4) 98 (57.7) 0.13
1a/b 11 (3.3) 1 (0.6) 10 (5.9) 0.01
1b 117 (35.5) 70 (43.8) 47 (27.7) 0.002
Liver disease indicators
ALT (U/L) 69 (45, 108) 60 (40, 88) 74.5 (52, 139) <0.001
AST (U/L) 52 (37, 79) 51.5 (35.5, 71.5) 53 (38, 87) 0.08
Alk phosphatase (U/L) 79 (62, 103) 83 (62, 108) 78 (63, 96) 0.043
Total bilirubin (mg/dL) 0.6 (0.5, 0.8) 0.6 (0.4, 0.8) 0.7 (0.5, 0.9) 0.004
INR (m = 2) 1.0 (0.9, 1.1) 1.0 (0.9, 1.1) 1.0 (0.9, 1.1) 0.95
WBC count (103/mL) (m = 3) 6.0 (4.7, 7.3) 5.7 (4.6, 7.3) 6.25 (4.9, 7.4) 0.055
Platelet count (103/mL) (m = 4) 207.5 (161, 257) 212 (159, 268) 207 (161, 242) 0.33
Ferritin (ng/mL) (m = 2) 204 (96.8, 366) 246 (122, 422) 149 (78, 287) <0.001
Albumin (g/dL) (m = 2) 4.2 (4.0, 4.4) 4.2 (3.9, 4.4) 4.2 (4.0, 4.5) 0.004
Iron/TIBC (m = 8) 34.1 (26.2, 44.0) 33.9 (25.7, 41.9) 34.3 (26.4, 47.7) 0.18
Ishak fibrosis score (m = 1) 2 (1, 3) 2 (1, 3) 2 (1, 3) 0.85
Ishak fibrosis score ‡3 (m = 1) 123 (37.4) 58 (36.5) 65 (38.2) 0.74
Fat score (m = 1) 0 (0, 1) 0 (0, 1) 0 (0, 1) 0.19
Steatosis (>5 present) (m = 1) 209 (63.5) 97 (61.0) 112 (65.9) 0.36
Total HAI inflammation (m = 1) 8 (6, 10) 8 (7, 10) 9 (6, 11) 0.58
Iron score (m = 35) 0.09
0 157 (53.2) 66 (47.5) 91 (58.3)
1 115 (39.0) 62 (44.6) 53 (34.0)
2 23 (7.8) 11 (7.9) 12 (7.7)
Serum lipid measures
TG (mg/dL) 102.5 (75, 146) 105.5 (74.5, 151) 98.5 (76, 137) 0.21
LDLc (mg/dL) 115.1 (88.1, 137.3) 106.4 (83.4, 133.4) 118.7 (95.8, 141.5) 0.009
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Kruskal–Wallis tests. For all statistical tests, a P-value of
<0.05 was considered statistically significant.
Linear regression was employed to model each lipid
measure as a continuous outcome. Associations of lipid
profile measures with hepatic fat score were assessed using
linear regression with lipid profile measures as dependent
variables. In regression models, TG, HDLc and TC were
transformed to the natural logarithm (ln) scale to achieve
normality. Independent variables were transformed to make
associations with lipid profile measures linear and were
centred about their means. In multivariable analyses, a
stepwise selection approach was used for variable reduction.
Associations between predictors of interest and each serum
lipid measure were first evaluated for adjusting for race and
age. Accounting for race and age, variables not retained in
any final multivariable model included smoking status,
alcohol consumption, body mass index (BMI), diabetes status
and hypertension status, ALT, AST, total bilirubin, INR,
Ishak fibrosis as a continuous measure and steatosis as a
dichotomous measure (>5% fat involvement). All analyses
Table 1 (Continued)
Feature* Overall (n = 330) AA (n = 160) CA (n = 170) P
HDLc (mg/dL) 41.8 (33.7, 53.8) 42.3 (32.9, 54.6) 41.3 (33.8, 52.0) 0.66
TC (mg/dL) 185 (157, 207) 179 (153.5, 204.5) 187 (161, 209) 0.10
Dyslipidaemia 232 (70.3) 110 (68.8) 122 (71.8) 0.55
m, number with missing data; AA, African American; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI,
body mass index; CA, Caucasian American; HAI, histological activity index; HCV, hepatitis C virus; HDLc, high-density
lipoprotein cholesterol; INR, international normalized ratio; LDLc, low-density lipoprotein cholesterol; TC, total cholesterol; TG,
triglyceride, TIBC, total iron-binding capacity; WBC, white blood cell count.
*Each categorical variable is summarized as n (%) with P-values corresponding to a Pearsons chi-square test (nominal
variables) or the Jonckheere–Terpstra test (ordinal variables) or exact equivalents, where appropriate; each continuous var-
iable is summarized as a median (interquartile range) with a P-value corresponding to a Wilcoxon rank sum test.
For features with two or more categories, the global P-value is listed in the first row of the feature. Where the global P-value is
<0.05, P-values correspond to Pearsons chi-square with comparisons as follows:
Each health insurance status category compared to other categories combined.
§Less than high school vs high school degree or more; high school degree vs more than high school degree; some college vs
more than some college.
–Each genotype compared to other categories combined.
Fig. 1 Lipid measures by liver fat score. P-values correspond to a test of trend with fat score. [Trend test for triglyceride (TG),
high-density lipoprotein cholesterol, and total cholesterol on the natural log scale]. NOTE: Boxplots exclude three extreme TG
level outliers: 980 mg/dL (fat score = 0.5); 481 and 600 mg/dL (fat score = 1). [Correction made on 16 November 2010, after
online publication: amendment in the legend for figure 1].
 2010 Blackwell Publishing Ltd
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were conducted using Statistical Analysis Software (SAS)
version 9 (Carey, NC, USA) or STATA version 9 (College
Station, TX, USA).
RESULTS
Characteristics of the study cohort are summarized by race
(Table 1). AAs did not significantly differ from CAs by age,
gender, employment status, health risk behaviours (smoking
status and weekly alcohol consumption), viral level, AST,
INR, WBC count, platelet count, per cent iron/TIBC, Ishak
fibrosis, total HAI score, steatosis, TG, HDLc or TC. Com-
pared to CAs, a larger percentage of AAs had health insur-
ance coverage (87% vs 78%, P = 0.04), public health
insurance (31% vs 18%, P = 0.006), less education
(P = 0.008), a history of diabetes (15% vs 4%, P < 0.001) or
hypertension (40% vs 19%, P < 0.001) and higher preva-
lence of HCV subtype 1b (44% vs 28%, P = 0.002). As a
group, AAs had higher BMI (median 29.3 vs 27.4 kg/m2,
P < 0.001), higher alkaline phosphatase (median 83 vs
78 U/L, P = 0.043) and ferritin levels (median 246
vs 149 ng/mL, P < 0.001), and lower ALT (median 60
vs 74.5 U/L, P < 0.001), total bilirubin (median 0.06 vs
0.07 mg/dL, P = 0.004), albumin (median 4.2 vs 4.2 g/dL,
P = 0.004) and LDLc levels (median 106.4 vs 118.7 mg/dL,
P = 0.009) than CAs. The prevalence of dyslipidaemia was
70% overall and did not significantly differ by race.
Liver disease severity was associated with lipid profile
measures. (Figs 1 and 2) Patients with severe fibrosis tended
to have lower HDLc and TC levels compared to those without
severe fibrosis (median 39.4 vs 45.5 mg/dL, P = 0.002;
median 172 vs 188 mg/dL, P = 0.004, respectively).
(Fig. 1) In contrast, compared to patients with lower fat
scores, patients with higher fat scores tended to have higher
TG (medians 89, 97, 114.5 and 139.5 mg/dL, P < 0.0001
for trend: 0, 0.5, 1 and 2 or greater fat score, respectively)
and lower HDLc levels (medians 45, 40.1, 39.4 and
40.9 mg/dL, P = 0.01 for trend: 0, 0.5, 1 and 2 or greater
fat score, respectively). (Fig. 2).
Iron study measures were significantly associated with
lipid profile measures in multivariable models (ferritin: ln TG
b = 0.02, P = 0.003; and per cent iron/TIBC: ln HDLc
b = )0.01, P = 0.001). (Table 2) Furthermore, the associ-
ation between serum ferritin and LDLc levels significantly
differed by race (P < 0.0001), such that for a decline in LDLc
of 100 ng/mL, the increase in ferritin was significantly lar-
ger in CAs compared to AAs (CA: b = )3.4, P < 0.0001;
AA: b = )1.7, P = 0.0001). (Table 2).
Significant direct relationships were found between the
natural logarithm (ln) of TG and log10 viral level in unad-
justed (b = 0.11, P = 0.003) and multivariable regression
models (b = 0.09, P = 0.01). (Fig. 3 and Table 2) Other
factors associated with lipid profile measures in multivariable
models (Table 2) were aspects of histological liver disease,
including HAI inflammation that was inversely related to
LDLc and the ln of TC, severe Ishak fibrosis associated with
lower ln HDLc levels (b = )0.10, P = 0.006) and fat score
directly related to the ln of TG (b = 0.17, P < 0.001).
DISCUSSION
In this cohort of people with treatment-naı̈ve chronic HCV
genotype 1 infection, there was significant direct association
between HCV viral load and TG levels, the latter of which is
mainly present in VLDL. This is relevant to proposed bio-
logical mechanisms of HCV replication and secretion from
hepatocytes. Potentially important in the context of HCV-
induced liver damage, steatosis was also associated with
higher TG levels. In contrast to TG levels, other lipid profile
measures were lower among those with advanced liver dis-
ease as measured by hepatic fibrosis, fat involvement and
inflammation.
Fig. 2 Lipid profile measures by Ishak fibrosis score. P-values correspond to Wilcoxon rank sum tests of differences by fibrosis
score (Ishak fibrosis score ‡3 vs Ishak fibrosis score <3). NOTE: Boxplots exclude three extreme TG level outliers: 600 and 980
mg/dL (nonsevere fibrosis); 481 mg/dL (severe fibrosis). [Correction made on 16 November 2010 after online publication:
amendment in the legend for figure 2].
 2010 Blackwell Publishing Ltd
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The significant direct relationship between HCV titres and
TG levels is consistent with findings from in vitro work
suggesting that HCV is secreted from hepatocytes into the
serum complexed with VLDL [23–27]. In transgenic mouse
models, inhibition of the microsomal TG transfer protein by
exposure to HCV core protein has been proposed as a
mechanism of HCV-induced steatosis, a plausible basis for
associations between low beta-lipoprotein levels and chronic
HCV infection [26]. This mechanism is supported by two
epidemiological studies, which found inverse relationships
between steatosis and TC, TG, and apolipoprotein B levels in
a genotype 3-infected group, but not in genotype 1 [12,13].
In contrast, there was a direct relationship between TG and
liver fat score in the present study and in the larger Virahep-
C cohort [10]. The inconsistent relationships between
steatosis and TG among studies may be attributed to the
Virahep-C study being an exclusively genotype 1-infected
group and differences in the aetiology of steatosis by HCV
genotype [33,34]. Whereas steatosis is posited to occur
because of metabolic changes in genotype 1 infection,
studies suggest that steatosis associated with genotype 3
occurs by a direct viral-induced process.
The current study found associations between steatosis
and severe fibrosis with lower HDLc and severe fibrosis with
lower TC levels. These findings are consistent with other
findings from both non-HCV-infected [11,14] and chroni-
cally HCV-infected groups [12,13] that have associated liver
disease with lower levels of HDLc and TC. The inverse rela-
tionship between liver disease and non-TG lipid profile
measures may reflect the disruption of lipid and lipoprotein
metabolism because of liver damage, albeit by host factors
(e.g. poor nutrient intake, alcohol consumption or excess
body weight) or attributed to chronic HCV infection [35].
As potential indicators of liver damage, serum iron mea-
sures (ferritin and the per cent iron/TIBC) were related to the
lipid profile (TG directly, other lipid profile measures indi-
rectly). In addition, the iron measures were significantly
higher for those with severe fibrosis, steatosis or hepatic iron
deposition (data not shown). These findings are consistent
with a report from a non-HCV-exposed cohort, which found
significantly lower HDLc and higher TG levels in a group
with high ferritin levels of at least 100 ng/mL ferritin levels,
compared to those below this cutpoint [36]. Findings are
also consistent with another study of exclusively HCV-
infected people, which found a direct relationship between
ferritin and liver fat [37]. Other work using National Health
and Nutrition Examination Survey (NHANES) data has
reported associations between elevated ferritin and iron
saturation in HCV-infected, compared to a nonexposed
group of people [38–40]. These studies suggest a relationship
between serum iron measures, liver disease and the lipid
profile, which may be impacted by chronic HCV infection;
however, biological mechanisms are unclear.
This study is not without limitation. Given the cross-sec-
tional nature of this analysis, it is not possible to infer cau-
sation or temporality of relationships between lipid profile
and liver disease measures. Despite this limitation, this study
has a number of strengths in that it assessed factors asso-
ciated with lipid profile measures, which may have impli-
cations to proposed mechanisms of HCV entry into
hepatocytes, replication and secretion from hepatocytes into
the serum. In addition, the Virahep-C cohort, which by
design enrolled and treated approximately equal numbers of
AAs and CAs, afforded a unique opportunity to assess
whether factors associated with the lipid profile differed by
race.
Fig. 3 Relationship between triglyceride (TG) and hepatitis C virus (HCV) RNA levels. ln = natural log transformation. Back-
transformed, one log10 increase in HCV level corresponds to an 11.4 mg/dL TG increase on the raw scale.
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In conclusion, the current study found associations
between lipid profile measures and both HCV level and liver
disease measures. These findings may guide further investi-
gations into the impact of antiviral therapy on the lipid
profile, as well as the evaluation of lipid profile measures as
predictors of treatment efficacy.
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